ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.679,73
-0,25%
S&P 500
5.297,10
-0,21%
Dow Jones
39.869,38
-0,10%
Euro vs US Dollar
1,08668
-0,01%
Bitcoin
66.222,31
1,51%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. La Jolla Pharmaceutical Company (LJPC)

  7. La Jolla Pharmaceutical Company (LJPC) News

LJPC

La Jolla Pharmaceutical (LJPC)

La Jolla Pharmaceutical Company
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:LJPC
DatumZeitQuelleÜberschriftSymbolFirma
14/02/202316h07Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:LJPCLa Jolla Pharmaceutical Company
01/09/202214h39Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:LJPCLa Jolla Pharmaceutical Company
29/08/202218h31Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:LJPCLa Jolla Pharmaceutical Company
29/08/202218h10Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:LJPCLa Jolla Pharmaceutical Company
23/08/202223h01Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:LJPCLa Jolla Pharmaceutical Company
23/08/202223h01Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:LJPCLa Jolla Pharmaceutical Company
23/08/202223h01Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:LJPCLa Jolla Pharmaceutical Company
23/08/202223h01Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:LJPCLa Jolla Pharmaceutical Company
23/08/202223h01Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:LJPCLa Jolla Pharmaceutical Company
22/08/202215h32Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:LJPCLa Jolla Pharmaceutical Company
22/08/202215h22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LJPCLa Jolla Pharmaceutical Company
22/08/202215h20Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:LJPCLa Jolla Pharmaceutical Company
22/08/202215h09Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:LJPCLa Jolla Pharmaceutical Company
22/08/202214h55Business WireInnoviva Completes Acquisition of La Jolla PharmaceuticalNASDAQ:LJPCLa Jolla Pharmaceutical Company
15/08/202214h14Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:LJPCLa Jolla Pharmaceutical Company
15/08/202214h04Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LJPCLa Jolla Pharmaceutical Company
25/07/202214h40Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:LJPCLa Jolla Pharmaceutical Company
25/07/202214h35Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:LJPCLa Jolla Pharmaceutical Company
12/07/202212h10Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:LJPCLa Jolla Pharmaceutical Company
12/07/202212h01Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:LJPCLa Jolla Pharmaceutical Company
11/07/202221h47Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:LJPCLa Jolla Pharmaceutical Company
11/07/202213h36Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LJPCLa Jolla Pharmaceutical Company
11/07/202213h32Business WireInnoviva to Acquire La Jolla Pharmaceutical CompanyNASDAQ:LJPCLa Jolla Pharmaceutical Company
05/07/202223h52Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LJPCLa Jolla Pharmaceutical Company
17/05/202223h08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LJPCLa Jolla Pharmaceutical Company
16/05/202222h18Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LJPCLa Jolla Pharmaceutical Company
16/05/202222h15Business WireLa Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Corporate ProgressNASDAQ:LJPCLa Jolla Pharmaceutical Company
19/04/202200h33Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LJPCLa Jolla Pharmaceutical Company
19/04/202200h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LJPCLa Jolla Pharmaceutical Company
04/04/202223h40Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LJPCLa Jolla Pharmaceutical Company
 Showing the most relevant articles for your search:NASDAQ:LJPC

Kürzlich von Ihnen besucht

BIT
F17489
Vontobel Financial Produ...
NASDAQ
NANO
Nanometrics
BIT
UC567D
Unicredit Bank
COIN
TNREUR
LSE
17IY
Anz Bank 48
EU
D132S
D132S
NYSE
BNE
Bowne & Co
ASX
SYISSZ
EU
4408T
4408T
LSE
1020
NYSE
GGB
Gerdau
LSE
0FE2
Skue Sparebank
ASX
GBI
Genera Biosystems
BIT
P14Y18
BNP Paribas Issuance
NYSE
FGP
Ferrellgas Partners
LSE
46MH
Hsbc Bk.41
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten